Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Article | 13 September 2021
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
The PfSPZ Vaccine does not protect infants from infection with Plasmodium falciparum, the major cause of malaria.
Martina Oneko, Laura C. Steinhardt, Robert A. Seder